3rd Quarter - Amendment

SAREPTA THERAPEUTICS, INC. for SAREPTA THERAPEUTICS, INC.

Firm
Client
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 21, 2019 $150,000 Replaced
3rd Quarter - Amendment (this page) Oct 31, 2019 $150,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)

LobbyistCovered position, as disclosed
DIANE BERRY —
STACEY FRISK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2507 (116th), S. 2158 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.